Market Intelligence, Clinical Progress, and High-Purity Reagents for Parkinson's Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRRK2 G2019S drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRRK2 G2019S Mutant Recombinant Protein (Kinase Domain / Full-Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View LRRK2 G2019S Products |
| Gene Delivery | LRRK2 G2019S Promise-ORF / Lentivirus Full-length mutant ORF for stable cell line construction. |
View LRRK2 G2019S Products |
| Benchmark Ab | Anti-LRRK2 / Anti-pS935 Recombinant Antibody Pair For Western, ICC, and pathway engagement readouts. |
View LRRK2 G2019S Products |
| Validator | LRRK2 siRNA Set For knockdown and specificity verification. |
View LRRK2 G2019S Products |
| LRRK2 WT (Wild-Type Control) | Matched wild-type LRRK2 protein for selectivity counter-screening; >95% purity, HEK293 expressed. | View LRRK2 WT Products |
| LRRK1 (Selectivity Control) | Close homolog for kinase selectivity counter-screening. | View LRRK1 Products |
| Rab10 (Pathway Substrate) | Primary LRRK2 substrate for in vitro kinase assays; recombinant protein, sequence verified. | View RAB10 Products |
| SNCA (Alpha-Synuclein) | Convergent Parkinson's pathway target for combination therapy. | View SNCA Products |
Assay Challenges & Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Hyperactive Kinase Activity (G2019S mutation increases activity ~2-3x) | Purified active LRRK2 G2019S mutant protein; theoretical MW confirmed by Mass Spec; Ready for inhibitor IC50 determination. |
| Kinase Selectivity (LRRK2 vs LRRK1 off-target & Mutant vs WT) | Matched LRRK2 WT, G2019S mutant, and LRRK1 WT proteins available with >95% purity; Sequence Verified. |
| Cellular Context & CNS Penetration | LRRK2 G2019S Lentivirus and siRNA for stable cell line construction and knockdown validation; HEK293 expression ensures native glycosylation. |
| Safety Validation (Lung & kidney toxicity avoidance) | siRNA included for target engagement validation in peripheral tissue models; Endotoxin-controlled proteins (<1 EU/μg) prevent false positives. |
| False Positives in Cellular Assays | Validated siRNA and Endotoxin-Controlled proteins for specificity confirmation. |
Live LRRK2 G2019S R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRRK2-targeted therapeutics is intensifying, with major players shifting focus from symptomatic management to disease-modifying kinase inhibition. First-generation LRRK2 inhibitors (e.g., Denali/Biogen's BIIB122) are advancing through Phase I/II trials in G2019S carrier and idiopathic Parkinson's cohorts. The next wave includes highly specific G2019S mutant inhibitors and antisense oligonucleotides (ASOs) to avoid peripheral toxicity from wild-type LRRK2 inhibition. R&D is also targeting blood-brain barrier optimization, biomarker-driven patient stratification via CSF pS935, and refined mutant-specific engagement profiles.
Competitive Modality & Indication Snapshot
The following snapshot connects prevailing market trends to their underlying assay requirements.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitor (Type I/II) | Denali / Biogen, Bayer | Parkinson's Disease (G2019S & Idiopathic) | In vitro Kinase Assay (Need high-purity LRRK2 G2019S & WT proteins) |
| PROTAC / Targeted Degradation | Emerging Biotech / Academia | Parkinson's Disease | Cellular Degradation Assay (Need LRRK2 G2019S Lentivirus stable line) |
| Allosteric / Non-ATP Competitive Inhibitor | Preclinical Programs | Parkinson's Disease | Conformation-specific Binding Assay (Need full-length native protein) |
| Antisense Oligonucleotides (ASO) | Biogen, Ionis | Neurodegenerative Disorders | Knockdown Validation (Need siRNA controls) |
| Gene Therapy | Prevail Therapeutics (Lilly) | Parkinson's Disease | Expression tracking (Need sequence verified Abs) |